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0954-6111/ª 2014 Elsevier Ltd. All rigBackground: Clinical management of community-acquired pneumonia (CAP) is increasingly
complicated by antibiotic resistance. CAP due to pathogens resistant to guideline-recom-
mended drugs (CAP-DRP) has increased. 2005 ATS/IDSA guidelines introduced a new category,
healthcare-associated pneumonia (HCAP), and recommend extended-spectrum antibiotic
treatment for patients meeting HCAP criteria. However, the predictive value of the HCAP
model is limited and data suggest that outcomes are not improved using HCAP guideline-
concordant therapy. Better methods to predict risk of CAP-DRP are needed.
Methods: We reviewed currently published literature on the performance status of HCAP as a
predictive tool and studies describing additional risk factors for CAP-DRP. We also summarize
the performance characteristics of the currently published alternative clinical prediction
scores and compare them to that of the HCAP model.
Results: In addition to the five risk factors incorporated in HCAP, at least 13 other factors have
been identified. The independent predictive value of any single factor is low, but accumulating
factors results in increased risk of CAP-DRP. The performance characteristics of 9 clinical pre-
diction scores are reviewed. Nearly all of the scores outperformed HCAP in their study popula-
tions. However, no single model has yet demonstrated adequate specificity to minimize
unnecessary antibiotic use, while retaining sufficient sensitivity to prevent inadequate initial
empiric antibiotic therapy when validated across a wide range of CAP-DRP prevalence.
Conclusions: Additional development and validation of prediction scores based upon more
refined risk factors for CAP-DRP is needed. Once an accurate, adequately validatedfectious Diseases, Intermountain Medical Center, 5121 S. Cottonwood Drive, Murray, UT 84157, USA.
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Pneumonia accounts for more than 1 million hospitaliza-
tions and 55,000 deaths per year in the United States [1,2].
Initial guidelines for inpatient management of community
acquired pneumonia (CAP) were developed in 1993 [3].
Concordance with these guidelines in hospitalized patients
with CAP, i.e. a b-lactam plus macrolide or respiratory
fluoroquinolone, is associated with improved outcomes
[4]. Since 1993, clinical management of pneumonia has
become more complex due to increasing rates of drug
resistance. Revised guidelines have aimed to identify pa-
tients at risk for infection with pathogens resistant to
antibiotics recommended for CAP (CAP drug-resistant
pathogens or CAP-DRP). However, the HCAP model has
limited predictive value and has not been shown to
improve outcomes [5]. Better methods of predicting risk
for CAP-DRP are needed.
Changing epidemiology of drug-resistant
organisms
Streptococcus pneumoniae is the predominant pathogen in
CAP, followed by Haemophilus influenzae, Moraxellacatarrhalis and atypical bacteria such as Mycoplasma
pneumoniae and Legionella pneumophila [6]. Since the
1990’s, the incidence of CAP-DRP has increased, notably in
patients with co-morbidities and frequent healthcare
exposure. This trend was originally described in patients
transferred from nursing homes and other long-term facil-
ities, in whom Enterobacteriaceae, Pseudomonas aerugi-
nosa and methicillin-resistant Staphylococcus aureus
(MRSA) were more frequently recovered [7,8].
In 2005, Kollef et al. reported data from a commercial
healthcare database of 3209 patients admitted from the
community with culture-positive pneumonia in 59 U.S. hos-
pitals [9]. In contrast to previous cross-sectional studies, this
study reported a high overall prevalence of CAP-DRP (34%), of
which MRSA and P. aeruginosa comprised the large majority
[9]. Although the accuracy of themicrobiology data has been
criticized because S. aureus and P. aeruginosa were more
prevalent than S. pneumoniae even in CAP patients [10], this
study raised concerns that a growing number of patients are
at risk for pneumonia due to CAP-DRP and may not receive
effective antibiotic therapy with CAP-concordant regimens.Appropriate initial antibiotic therapy
Initial selection of empiric antibiotics with activity against
the infecting organism improves outcomes in serious bac-
terial infections. This has been demonstrated in multiple
clinical settings, including infections in the critically ill
[11], bacteremia [12], and for treatment of MRSA [13], P.
aeruginosa [14], and extended-spectrum beta-lactamase
(ESBL) producing Enterobacteriaceae [15]. In pneumonia
populations with elevated CAP-DRP prevalence, inadequate
initial antibiotic therapy is associated with poor outcomes,
including mortality [16,17].
Table 1 HCAP criteria diagnostic performance by prevalence.
Author (location) Prevalence (%) Sensitivity (%) Specificity (%) PPV (%) NPV (%)
Micek (St. Louis) 50.7 88 53.7 66.1 81.3
Shorr (St. Louis) 45.2 86.9 48.6 58.2 81.7
Kollef (US Database) 34 54.5 75.1 49.3 78.8
Schreiber (Washington D.C.) 31.6 78.3 56.2 45.2 84.9
Jung (Korea) 26.5 67.4 57.9 36.7 83.1
Shindo (Japan) 15.8 67.5 64.9 26.6 91.4
Shindo (Japan) 12.9 73.9 61.3 22.1 94.1
Grenier (Canada) 5.3 32.9 83.9 10.2 95.7
Chalmers (UK) 4.9 55 80 12.4 97.2
Carratala (Spain) 1.4 50 80.3 3.5 99.1
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In 2005, pneumonia guideline classifications were sub-
divided to add a novel entity, healthcare-associated
pneumonia (HCAP), to the existing paradigm [18]. This new
category comprises a patient population with frequent
healthcare exposure in whom the risk of CAP-DRP is
increased. The criteria used for HCAP classification were
based upon risk factors for drug-resistant bacteremia
identified by Friedman et al. [19] and subsequently applied
to the large U.S. cohort described by Kollef et al. [9] HCAP
criteria include: patients hospitalized within the last 90
days, those receiving chemotherapy, wound care or
intravenous antibiotics, residents of nursing homes or
long-term facilities, and patients requiring hemodialysis.
The guidelines recommend that HCAP patients be treated
with an anti-pseudomonal beta-lactam plus either an
aminoglycoside or an anti-pseudomonal fluoroquinolone,
plus an agent active against MRSA if risk factors for MRSA
are present [18].
Subsequent studies have confirmed that the HCAP
designation effectively identifies a population with multi-
ple co-morbidities and increased mortality [16,20e27].
However, unlike CAP, for which guideline-concordant
therapy has been repeatedly shown to improve mortality
[4,28,29], HCAP guideline-concordant therapy has not
been shown to improve outcomes [20e22,27,30e37], and
may in fact be associated with increased mortality.
Although this remains incompletely understood, there are
several potential explanations for these results. First, poor
outcomes in the HCAP population appear to be more
closely associated with comorbid disease than to resistant
organisms. This was demonstrated by Rello et al., [39] who
showed that even in a population limited only to patients
with confirmed pneumococcal pneumonia, outcomes were
poorer in those meeting HCAP criteria. This was confirmed
in a meta-analysis by Chalmers et al. who showed no dif-
ference in mortality between CAP and HCAP when
adjusted for age and co-morbidity [5,38]. Second, unnec-
essary extended-spectrum antibiotic therapy increases
cost [20,32], drug toxicity [39e41], Clostridium difficile
infection [42], and antibiotic resistance [43], which may
affect outcomes.
Lastly, accumulating evidence suggests that the HCAP
model is poorly predictive of pneumonia due to CAP-DRP
[5,25,44]. The predictive value of the HCAP criteria variesdirectly with the local incidence of CAP-DRP (Table 1). The
positive predictive value (PPV) of the HCAP classification is
only satisfactory in areas with very high rates of CAP-DRP,
at the expense of an unacceptable negative predictive
value (NPV) [9]. Conversely, in areas of low-moderate CAP-
DRP incidence, the HCAP-CAP distinction is effective in
identifying patients at low risk of drug resistant disease,
but results in over-treatment in many patients [25,30]. In a
recent meta-analysis of 24 studies, Chalmers et al.
confirmed the relatively poor performance of HCAP as a
predictor of CAP-DRP, reporting an overall sensitivity of
53.7, specificity of 71.2 and AUROC of 0.70 [5]. Alternative
strategies are needed to accurately discriminate patients
at risk for CAP-DRP pneumonia from patients for whom CAP
therapy is most appropriate.Risk factors for CAP-DRP
Data from HCAP studies reproducibly identify risk factors
associated with pneumonia caused by CAP-DRP (Table 2)
[16,20,21,23e27,30,31,34,36,37,44e47]. Risk factors fall
into several categories: extrinsic (environmental),
intrinsic (host), and factors selective specifically for CAP-
DRP (Fig. 1). For example, environmental exposures such
as recent hospitalization or residence in a long term care
facility contribute to oropharyngeal colonization with
potentially drug-resistant organisms [48,49]. Additional
extrinsic factors favoring colonization with CAP-DRP
include wound care [27], tube feeding [50], presence of
an indwelling catheter [48], and invasive healthcare
intervention in general [51]. Many of these extrinsic risk
factors are collinear, and are often present in combination
in debilitated patients.
Intrinsic risk factors alter host physiology to non-
specifically increase risk of developing pneumonia caused
by any microorganism, including CAP-DRP if present in the
oropharynx. Intrinsic factors include age, aspiration risk,
chronic lung disease, gastric acid suppression, immuno-
suppression, diabetes and cognitive impairment. Some host
factors such as poor functional status [8,48,51], cortico-
steroid use [24] and bronchiectasis tend to foster coloni-
zation more specifically with CAP-DRP.
Prior antibiotic use is a well-established risk factor for
both colonization and infection with multi-drug resistant
organisms. In pneumonia specifically, antibiotic usage
Table 2 Risk factors for CAP-DRP by publication.
Risk factor Reference(s)
Prior antibiotics [16,23e25,30,36,37,44e46,51]
Prior hospitalization [23,25,26,31,34,36,37,44e47]
Resident of long term care [24,25,30,31,34,36,44,45,47]
Tube feeding [16,23,36,37]
Multiple HCAP risk factors [20,27,30,34e37,47]
Chronic lung disease [21,24,30,34,36,46,47]
Immunosuppression [25,30,36,37,46]
Chronic kidney disease/
hemodialysis
[25,31,34,47]
Wound care [27,36]
Infusion therapy [24]
Poor functional status [16,37,51]
Aspiration risk [21]
Diabetes mellitus [24,45]
Tobacco use [46]
Severity of pneumonia [24,31,35,45]
Cerebrovascular disease [45,47]
Cognitive impairment [45]
Prior CAP-DRP or MRSA
colonization
[24,37,54]
Gastric acid suppression [37]
Indwelling catheter [48]
4 B.J. Webb et al.exerts selective pressure favoring CAP-DRP in the oropha-
ryngeal microcosm [43,44,51].
Overall, the independent predictive value for CAP-DRP
for most risk factors is low. However, the cumulative risk
of infection due to CAP-DRP increases with the presence
of multiple risk factors [20,27,30]. A confluence of
extrinsic and intrinsic risk factors with selective antibioticCumula
CAP-D
Risk
Selective A
Press
Extrinsic (Environment) 
Factors
Prior Hospitalization
Long  Term Care
Tube Feeding
Wound Care
Infusion Therapy
Indwelling Catheter
Hemodialysis
Figure 1 Interplay of Cpressure leads to the highest risk for disease due to
CAP-DRP.
Prediction of CAP-DRP
A viable alternative to the HCAP model should accurately
distinguish patients at low risk for CAP-DRP from those at
high risk for whom extended-spectrum therapy is war-
ranted. An ideal predictive model would be derived from
risk factors specifically associated with CAP-DRP, validated
across demographically- and microbiologically-distinct
populations, be easily calculated, and able to distinguish
risk of MRSA from other CAP-DRP. Current scoring models
are either cumulative, in which risk factors are weighted
equally and probability of CAP-DRP increases with the
number of factors, or probabilistic, in which risk factors are
weighted from results of regression analysis in the deriva-
tion group. Electronic decision support might ease the
burden of calculation if a complex model performs better
than simple models such as HCAP [52].
Methodology used to evaluate the clinical utility of a
predictive model must be carefully considered. Ideally, a
prediction tool establishes a threshold below which the risk
of CAP-DRP is acceptably low in order to avoid inadequate
treatment in most cases, but above which the probability of
CAP-DRP is high enough to justify extended-spectrum an-
tibiotics. Although a predictive model may demonstrate
good overall accuracy by area under the receiver-operator
curve (AUROC), it may be unable to clearly dichotomize
high and low risk. This is due in part to the bell-shaped
rather than binary curve of probability distribution. Also,
the lack of specificity among risk factors contributes to a
see-saw effect in which specificity is augmented at the
expense of sensitivity as the threshold is raised.tive 
RP 
ntibiotic 
ure
Intrinsic (Host) 
Factors
Chronic Lung Disease
Immunosuppression
Aspiration
Gastric Acid Suppression
Cognitive impairment
Cerebrovascular disease
Poor Functional Status
MRSA Colonization
Prior CAP-DRP
Tobacco Use
Diabetes
AP-DRP risk factors.
Table 3 Clinical prediction models.
Model
(author,
year)
Original
reference
Validation
reference(s)
Population(s),
(n Z culture-positive
cases)
Risk factors Points Design Prediction
cut-off
(points)
CAP-DRP
prevalence
(%)
Sens
(%)
Spec
(%)
PPV
(%)
NPV
(%)
AUROC
Niederman,
2009
[53] [35] Japan, (n Z 195),
prospective multicenter
cohort; HCAP
patients only; stratified
by severity
Hospitalization (90 d)
Poor functional status
Antibiotic use (180 d)
Immunosuppression
1
1
1
1
Cumulative
decision
tree
Severe
PNA  1
Non-severe
PNA  2
Overall: 25.1
Severe: 37.7
Non-severe:
16.9
93.9
96.5
90.0
55.5
50.0
58.2
41.4
53.8
30.5
94.6
96.0
96.6
N/A
Shorr,
2008
[31] [25] USA - St. Louis, (n Z 977),
retrospective single center
Hospitalization (90 d)
Resident of LTC
Hemodialysis
Severe PNA (ICU)
4
3
2
1
Probabilistic 1 46.7 88.6 54.5 63.0 84.5 0.71
[34] Spain - Barcelona (n Z 493)
prospective multicenter
7.7 86.8 75.4 22.8 98.6 0.89
[56] ItalyeMilan (n Z 180),
prospective multicenter
18.3 60.6 76.9 37.0 89.7 0.70
Schreiber,
2010
[30] N/A USAeWashington DC,
(n Z 190), retrospective
single center; only ICU
patients
Immunosuppression
Resident of LTC
Antibiotic use
3
2
1
Probabilistic 2 31.5 63.3 70.0 49.4 80.5 0.71
Aliberti,
2012
[47] [47] ItalyeMilan (n Z 180),
prospective multicenter
CVA, DM, COPD,
Antibiotic use (90 d),
wound care
immunosuppression
0.5 Probabilistic >0.5 18.3 78.8 70.0 37.1 93.6 0.79
[34] Spain - Barcelona
(n Z 496), prospective
multicenter
Resident of LTC
Hospitalization (90 d)
Chronic renal failure
3
4
5
7.7 78.9 86.2 32.3 98.0 0.89
Shindo,
2013
[37] N/A Japan (n Z 746), p
rospective multicenter
MRSA Risk Factors:
Hospitalization (90 d)
Antibiotic use (90 d)
Hemodialysis (30 d)
Prior MRSA colonization
Congestive heart failure
Gastric acid suppression
1
1
1
1
1
1
Cumulative 2
3
2 þ 1
MRSA RF
3 þ 1
MRSA RF
(All Cases):
10.3
(þ1
MRSAeRF):
24.8
74.0
41.6
82.8
41.4
70.4
87.9
58.0
81.8
22.4
28.3
39.3
42.9
95.9
92.9
91.1
81.0
0.76
Other CAP-DRP risk
factors:
Hospitalization (90 d)
Antibiotic use (90 d)
Immunosuppression
Gastric acid suppression
Tube feeding
Poor functional status
1
1
1
1
1
1
2
3
All CAP-DRP
16.0
73.1
47.1
73.2
90.9
34.2
49.6
93.5
90.0
0.79
(continued on next page)
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Table 3 (continued )
Model
(author,
year)
Original
reference
Validation
reference(s)
Population(s),
(n Z culture-positive
cases)
Risk factors Points Design Prediction
cut-off
(points)
CAP-DRP
prevalence
(%)
Sens
(%)
Spec
(%)
PPV
(%)
NPV
(%)
AUROC
Park,
2012
[50] [36] Korea (n Z 580),
retrospective single
center
Tube Feeding
Hospitalization (90 d)
Intravenous antibiotics
(30 d)
Resident of LTC
Chemotherapy (30 d)
Wound care (30 d)
Hemodialysis
5
3
2
1
1
1
1
Probabilistic 3 39.1 63.9 74.2 61.4 76.2 0.73
El Solh,
2004
[51] [51] USAeBuffalo, NY
(n Z 86 -derivation;
n Z 47-validation).
Prospective, single
center, Patients with
severe NHAP
Antibiotic use (180 d)
Functional status
1
1
Cumulative
decision
tree
2 19.8 52.9 98.6 90.0 89.7 0.90
Shorr
MRSA,
2013
[45] [45] USA, (n Z 3993 -
derivation, n Z 1982
-validation) retrospective,
multi-center database
cohort
Hospitalization (90 d)
Severity (ICU)
Resident of LTC
Extremes of age
(<30, >79)
Intravenous antibiotics
(30 d)
Cerebrovascular disease
Dementia
Diabetic female
2
2
1
1
1
1
1
1
Probabilistic 2 14.1 59.1 60.0 19.2 90.1 0.64
Madaras-
Kelly,
2012
[24] N/A USA (n Z 375),
retrospective multicenter
VA. Only included HCAP
patients
MRSA colonization
(<90 d)
MRSA colonization
(>90 d)
Resident of LTC
(<180 d)
Infusion Therapy
(30 d)
Cephalosporin use
(<365 d)
Diabetes Severe
PNA (ICU)
100
45
45
35
30
30
25
Probabilistic Score %
CAPDRP
<35 <20%
35e90 20e40%
90e130
40e60%
130e185
60e80%
185e230
80e90%
>230 >90%
31.5 NA NA NA NA 0.71
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Several clinical prediction models have been developed to
improve upon the performance of the HCAP criteria (Table 3)
[24,25,30,31,34e37,45,47,51,53]. While most scores demon-
strate better test performance when compared to HCAP, a
model able to sensitively predict CAP-DRP while minimizing
unnecessary antibiotic coverage has yet to be validated.
The first predictive model was proposed by El-Solh et al.
prior to HCAP guideline publication [51]. This cumulative
decision tree model was prospectively derived and
validated in a small cohort of nursing home patients
admitted with severe pneumonia. Using functional status
and recent antibiotic use (within180 days), the El Solh
model yielded positive and negative predictive values of
90% and an AUROC of 0.90. However, a significant decrease
in test performance would be expected if applied beyond
this narrow population with elevated risk of CAP-DRP.
The first of several probabilistic clinical prediction
scores was derived and validated [25] in large, single-
center, retrospective cohorts with CAP-DRP prevalence
>45% using risk factors weighted according to strength of
correlation in logistic regression analysis. Using hospitali-
zation, long term care, hemodialysis and severity as risk
factors, the Shorr model significantly improved upon the
specificity of the HCAP criteria (54.5% vs 34.3%) with only a
marginal decrease in sensitivity. Unnecessary extended-
spectrum antibiotic therapy would have been reduced
from 30% to 24.3% compared to HCAP in this observational
study in a high-prevalence population [25]. In subsequent
evaluations in four distinct populations with lower rates of
CAP-DRP [34,37,47], the score outperformed HCAP, rec-
ommending inadequate therapy in 1e7% and overtreatment
in 19e23% of cases.
Aliberti et al. employed similar methodology to derive a
predictive model in a prospective Italian cohort, heavily
weighting chronic renal disease, recent hospitalization and
long term care but also including minor risk factors such as
cerebrovascular accident, diabetes mellitus, chronic
obstructive pulmonary disease, wound care, immunosup-
pression and antibiotic use [47]. The model was validated in
an independent, prospective, multinational population
with a very low CAP-DRP prevalence (7.7%) where it out-
performed the HCAP criteria. In this setting, the Aliberti
score would potentially reduce inappropriate therapy to
<2% of all cases while limiting use of unnecessary
extended-spectrum antibiotic treatment to 12.7%. The
Aliberti and Shorr models demonstrated similar perfor-
mance characteristics in this population [34].
Park et al. derived a probabilistic scoring model by
weighting the six HCAP criteria in addition to a novel risk
factor, tube feeding [50]. In a retrospective validation
study in a high-prevalence population, this model demon-
strated marginal improvement over HCAP (PPV 61.4%
vs. 56.9%). Overtreatment would have only been reduced
from 50.7% to 43.7% using this model, and low sensitivity
(63.9%) and high CAP-DRP prevalence in this population
resulted in a NPV of only 76.2% [36].
Two additional probabilistic scores, proposed by
Schreiber [30] and Madaras-Kelly [24], have not yet been
independently validated. The Schreiber score is comprisedof weighted factors including immunosuppression, long term
care and antibiotic use. In a single center derivation cohort
of patients admitted to the ICU with severe pneumonia with
a CAP-DRP rate of >30%, this score demonstrated a PPV of
49.4% at the expense of a relatively low NPV of 80.5%;
under- and over-treatment were recommended in 11.5% and
20% of cases using this model. The Madaras-Kelly model was
retrospectively derived from HCAP patients, and included
risk factors MRSA colonization, long term care, infusion
therapy, cephalosporin use, diabetes and severity. The au-
thors reported an AUROC of 0.71, a similar test performance
as reported for other published scores.
A decision tree algorithm previously published [53] has
recently been evaluated in a prospective implementation
study [35]. The Niederman model retains the HCAP/CAP
distinction, but further stratifies HCAP patients according
to CAP-DRP risk on the basis of additional risk factors
including antibiotic use within 180 days of admission, hos-
pitalization within 90 days, poor functional status and
immunosuppression. This model assigns a lower threshold
for extended-spectrum therapy in patients with severe
disease. When implemented in a multi-center Japanese
cohort comprised of 195 HCAP patients with bacterial
pneumonia, the algorithm limited inadequate empiric
therapy to 1.5%, but resulted in unnecessary extended-
spectrum antibiotic therapy in 65/195 (33%) of cases [35].
Another recent publication describes a cumulative
model derived from a large, prospective multicenter
Japanese cohort [37]. Shindo et al. assigned one point
each to the following risk factors: hospitalization within 90
days, antibiotic use within 90 days, immunosuppression,
gastric acid suppression, tube feeding and poor functional
status. The risk of pneumonia due to a CAP-DRP was then
calculated according to the total score. In a population
with an overall CAP-DRP prevalence of 16.6%, a score
threshold of 2 demonstrated a NPV of 93.5% and a PPV of
34.2%. Antibiotic prescribing according to this score would
have resulted in inadequate initial therapy in 4% of pa-
tients, and unnecessary antibiotic coverage in 22.5%. This
model has not been validated in an independent
population.Predicting risk of MRSA
Several models have attempted to differentiate risk for
MRSA from other CAP-DRP such as P. aeruginosa. Shindo
et al. found that in addition to risk factors common for all
CAP-DRP, hemodialysis, prior MRSA colonization and
congestive heart failure were uniquely associated with
increased risk of MRSA. In patients with 2 or more risk
factors for CAP-DRP, the presence or absence of at least
one MRSA-specific risk factor resulted in a PPV for MRSA
pneumonia of 39.3%, and NPV of 91.1%. Shorr et al. [45]
derived a MRSA-specific prediction model from a large
retrospective database cohort, and found that odds of
MRSA pneumonia were increased in patients with recent
hospitalization, severe pneumonia, long-term care, ex-
tremes of age, recent intravenous antibiotic use, cerebro-
vascular disease, dementia and diabetic females. In a
validation cohort, a probabilistic scoring model based on
8 B.J. Webb et al.these risk factors demonstrated a PPV of 19.2% and NPV of
90.1% in a population with 14.1% prevalence. In this cohort,
the novel MRSA score did not perform better than the HCAP
criteria. Given the lack of specificity of risk factors for
MRSA, point of care determination of nasal MRSA coloni-
zation may prove to be a more accurate method of deter-
mining MRSA risk. A recent retrospective study found that
detection of nasal MRSA colonization by polymerase chain
reaction (PCR) had a PPV of nearly 40% and NPV of >98% for
clinical MRSA pneumonia [54]; further study is warranted.Future research
Additional research is needed in order determine the
optimal method of identifying patients with pneumonia at
highest risk for CAP-DRP. Rapid molecular-based diagnostic
testing holds promise as a means both for guiding appro-
priate therapy and deescalating from broad spectrum
therapy [54]. Assays employing multiplex PCR or 16s RNA
amplification techniques to detect respiratory pathogens or
genetic determinants of resistance directly from respira-
tory specimens are under investigation [55]. The diversity
of gram-negative resistance mechanisms and the number of
potential CAP-DRP implicated in pneumonia are a signifi-
cant challenge for novel diagnostic testing development.
The majority of these techniques have yet to be validated
and remain several years from routine clinical practice.
Until then, improving the accuracy of clinical prediction
models should remain the focus of clinical research as a
means of optimizing pneumonia management while
reducing antibiotic over-utilization. Additional refinement
of CAP-DRP risk factors is necessary. For example, although
recent hospitalization and antibiotic use are both associ-
ated with risk for CAP-DRP, the time elapsed from exposure
to pneumonia admission may be an important contributor,
perhaps to be integrated as a continuous variable in scoring
algorithms. Likewise, the class of prior antibiotic exposure
or type of hospitalization (ICU versus medical/surgical
ward) may also impact magnitude of risk and specificity of
the risk factor.
Antibiotic overtreatment will always be favored over
inadequate empiric therapy given the evidence of poor
outcomes with the latter. In order to reduce cost, prevent
resistance and limit adverse effects, additional research is
needed to guide safe and timely antibiotic de-escalation in
culture-negative patients with intermediate to high CAP-
DRP risk.
Nearly all of the recently published predictive models
have outperformed HCAP in their respective study pop-
ulations. However, no single model has yet demonstrated
adequate specificity to minimize unnecessary antibiotic
use, while retaining sufficient sensitivity to prevent inad-
equate initial empiric antibiotic therapy when validated
across a wide range of CAP-DRP prevalence. Head-to-head
validation studies will be necessary in order to evaluate
these models’ generalizability and performance. With some
refinement, development of a score capable of differenti-
ating high and low CAP-DRP risk in diverse validation pop-
ulations is conceivable. Prospective implementation studies
of scores with acceptable performance in validation studies
will then be key to determine whether patients benefit.Conclusion
Clinicians are increasingly faced with the difficult decision
of which patients to treat with CAP antibiotic regimens, and
which patients might benefit from empiric extended-
spectrum therapy. Although the HCAP model correctly
identifies a population prone to poor outcomes, it does not
adequately predict risk for CAP-DRP. Novel methods are
needed in order to avoid unnecessary broad spectrum
antibiotic use while minimizing empiric therapy lacking
activity against drug-resistant pathogens. Although multi-
ple prediction models have been proposed that improve
upon HCAP criteria, none has yet been validated across
broad microbiological and demographic populations. Addi-
tional research is necessary in order to refine scoring
models and identify alternatives to HCAP with wide clinical
generalizability. Once validated, interventional trials will
be needed to evaluate safety and performance.
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